Logo

MedImmune

AstraZeneca Launches Genomics Initiative to Drive Drug Discovery and Development
Premium

The pharma company will analyze genomic and clinical data from 2 million individuals over the next 10 years to drive drug development across its entire portfolio. 

Cepheid, MedImmune, COMBACTE Ink Bacterial Dx Collaboration

Cepheid will create Xpert cartridge tests to detect S. aureus and P. aeuginosa, to be used in clinical trials for biologics intended to prevent pneumonia.

Now Part of AstraZeneca, Definiens Concentrating on CDx, Ramp up into Clinical Space
Premium

While the deal has provided AstraZeneca and MedImmune access to the tissue phenomics technology, Definiens now has broader and clearer access to patients.

 

AstraZeneca's MedImmune Acquiring Definiens for at Least $150M

NEW YORK (GenomeWeb) – AstraZeneca today announced its biologics research and development arm MedImmune has reached a deal to purchase digital pathology products firm Definiens.

AstraZeneca, U of Cambridge Collaboration to Include R&D into Neurodegenerative Diseases

NEW YORK (GenomeWeb) – AstraZeneca and its wholly owned subsidiary MedImmune announced on Thursday collaborations with the University of Cambridge, including one aimed at research into neurodegenerative diseases.